Drug Profile
Brexucabtagene autoleucel - Kite Pharma
Alternative Names: Autologous anti-CD19-transduced CD3+ cells; Brexu-cel; Brexucabtageneautoleucel; KTE-X19; TecartusLatest Information Update: 23 Feb 2024
Price :
$50
*
At a glance
- Originator Cabaret Biotech
- Developer Kite Pharma
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Mantle-cell lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Phase II Burkitt's lymphoma; Haematological malignancies; Hairy cell leukaemia; Richter's syndrome; Solid tumours; Waldenstrom's macroglobulinaemia
- Phase I/II Non-Hodgkin's lymphoma
- Discontinued Chronic lymphocytic leukaemia
Most Recent Events
- 24 Jan 2024 Phase-II clinical trials in Precursor B-cell lymphoblastic leukaemia-lymphoma (Second-line therapy or greater) in Japan (IV) (NCT06253663)
- 24 Jan 2024 Phase-II clinical trials in Mantle-cell lymphoma (Second-line therapy or greater) in Japan (IV) (NCT06253663)
- 12 Dec 2023 Efficacy and adverse events data from the ZUMA-18 expanded access trial in Mantle-cell lymphoma released by Kite Pharma